Two lines low, reticulocytes low
30s, admitted for something else. Hemoglobin 6.5, MCV 64, platelets 85K, white count normal, reticulocytes low.
Reticulocyte: red cell 1 day out of the marrow. Low reticulocytes: the marrow is not making, so this is not bleeding or destruction. ATRA: all-trans retinoic acid. PNH: paroxysmal nocturnal hemoglobinuria.
Algorithm
Order tonight
- CBC with differential, smear to the lab
- Absolute reticulocyte count
- Immature platelet fraction
- Ferritin, iron, TIBC
- B12 with methylmalonic acid, folate
- Copper, zinc
- LDH, haptoglobin, bilirubin, direct Coombs
- PT, INR, fibrinogen
- Peripheral flow cytometry: PNH and blasts
- HIV, hepatitis B and C, parvovirus B19
- Pregnancy test
Write it like this
Bicytopenia with low reticulocyte count, consistent with decreased production. Severe iron deficiency explains the anemia but not the thrombocytopenia. Primary marrow process, including acute leukemia, must be excluded before discharge. Plan: IV iron, peripheral flow cytometry, hemolysis labs, bone marrow aspirate and biopsy with cytogenetics this admission. Source of iron loss: menstrual and GI history, celiac serology, GI evaluation.
Where people slip
- Iron deficiency explains the anemia. Do not let it explain away low platelets: a leukemia sent home is the miss you never get back.
- Folate before B12 fixes the blood and lets the nerves get worse.
- Blood from relatives if aplastic anemia is possible: they are future donors.
3 F: Fuel (iron, B12, folate, copper). Factory (aplastic anemia, myelodysplasia, PNH). Foreign cells (leukemia, lymphoma, cancer).
Sources
Retrieved from PubMed, read on Nov 9, 2026.
- Durrani J, Groarke EM, Sekeres MA. Bone marrow failure syndromes across the age spectrum. EClinicalMedicine 2026. doi:10.1016/j.eclinm.2026.104139
- Killick SB, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 2016. doi:10.1111/bjh.13853
- van den Akker M, et al. Thrombocytopenia in severe iron deficiency anemia in children. Health Sci Rep 2021 (pediatric series). doi:10.1002/hsr2.351
- Sanz MA, et al. Management of acute promyelocytic leukemia: updated European LeukemiaNet recommendations. Blood 2019. doi:10.1182/blood-2019-01-894980
Pancytopenia in the ICU
60s, septic shock last week, now off pressors. White count 2, hemoglobin 8, platelets 40, then 21, then 12.
Better patient, worse counts: it is not the sepsis anymore. 4T score (0 to 8) estimates heparin-induced thrombocytopenia. HScore estimates HLH, hemophagocytic lymphohistiocytosis, the immune storm that eats blood cells. DIC: disseminated intravascular coagulation. TTP: thrombotic thrombocytopenic purpura. HIT: heparin-induced thrombocytopenia. PLASMIC: 7-point TTP score.
Algorithm
Order today
- Smear review: clumps, schistocytes, nucleated red cells
- LDH, haptoglobin, fibrinogen, INR, D-dimer
- Reticulocytes, creatinine (PLASMIC score)
- PF4 antibody if 4T is 4 or more
- Ferritin, triglycerides, soluble CD25 if HLH possible
- Copper, zinc, B12, folate
- CMV, EBV, parvovirus B19 PCR
- Medication list with pharmacy
Write it like this
Progressive pancytopenia despite improving sepsis. Differential: drug-induced marrow suppression, copper deficiency, secondary HLH, marrow infiltration. No evidence of DIC or TMA; HIT unlikely by 4T score. Plan: viral PCRs, copper, triglycerides for HScore, medication review; bone marrow biopsy if counts keep falling.
Where people slip
- Ferritin 2,000 in sepsis is not enough for HLH. In the ICU, HLH sits around 9,000 and up, and even a high HScore is right only about 1 time in 5.
- Linezolid after 2 weeks, ganciclovir, trimethoprim-sulfamethoxazole, methotrexate with kidney failure: check the list before the marrow.
- Copper deficiency looks like myelodysplasia on the marrow. Check it before calling it a clonal disease.
Sources
Retrieved from PubMed, read on Nov 9, 2026.
- Knaak C, et al. HLH in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore. Crit Care 2020. doi:10.1186/s13054-020-02941-3
- Lachmann G, et al. Hyperferritinemia in critically ill patients. Crit Care Med 2020. doi:10.1097/CCM.0000000000004131
- Fardet L, et al. Development and validation of the HScore. Arthritis Rheumatol 2014. doi:10.1002/art.38690
- Halfdanarson TR, et al. Hematological manifestations of copper deficiency. Eur J Haematol 2008. doi:10.1111/j.1600-0609.2008.01050.x
- Zheng XL, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost 2020. doi:10.1111/jth.15006
Rectal cancer
28-year-old, rectal mass, biopsy adenocarcinoma, MRI T3N1, nothing in the chest or liver. What do you ask first?
dMMR: mismatch repair deficient; usually also MSI-high (microsatellite instability). FOLFOX, CAPOX: oxaliplatin with 5-FU or capecitabine. T: depth (T3 through the wall, T4 into organs). N: nodes (N1 1 to 3, N2 4 or more).
Algorithm
The two dostarlimab studies
| Memorial Sloan Kettering | AZUR-1 | |
|---|---|---|
| Design | One center, phase 2 | Many centers, phase 2 |
| Patients | 12 in 2022; 49 rectal by 2025 | 154 |
| Complete response at end of treatment | 49 of 49 | not reported |
| Overall response | 100% | 79%central review; 82% investigators |
| Complete response still there at 12 months | 93%FDA review, 50 patients | 47 to 68%central review 47%, investigators 68% |
| Dose | 500 mg IV every 3 weeks, 9 doses (6 months). FDA approved Oct 19, 2026, for stage II to III. | |
Why the gap: AZUR-1 used an independent central review as well as investigators, across many centers instead of one. Tell the patient: most respond, about half to two thirds still have no tumor at 1 year, and surgery stays available.
Order before tumor board
- Rectal protocol MRI
- CT chest, abdomen, pelvis; CEA
- Mismatch repair staining on the biopsy
- Genetics referral (under 50: germline panel for everyone)
- Fertility referral before any treatment
- Before PD-1 blockade: TSH, cortisol, liver tests, hepatitis B and C; pregnancy test
Write it like this
Rectal adenocarcinoma, clinical T3N1M0, mismatch repair deficient. Recommend PD-1 blockade with dostarlimab with intent of organ preservation, restaging with MRI, endoscopy and CT at weeks 6 and 12 and after dose 9. Germline testing for Lynch syndrome and fertility preservation before therapy. Tumor board.
Where people slip
- Chemoradiation booked before the staining is back. In a dMMR tumor it may be radiation the patient never needed.
- Promising 100%. That was one center. Quote AZUR-1.
- Watch and wait without watching: 94% of regrowths come in the first 2 years.
Stain before you plan. Young patient, three calls: genetics, fertility, tumor board.
Sources
Retrieved from PubMed and FDA news reports, read on Nov 9, 2026.
- Cercek A, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022. doi:10.1056/NEJMoa2201445
- Cercek A, et al. Nonoperative management of mismatch repair-deficient tumors. N Engl J Med 2025. doi:10.1056/NEJMoa2404512
- FDA accelerated approval of dostarlimab for dMMR or MSI-high locally advanced rectal cancer, AZUR-1 (NCT05723562). OncLive, Oct 19, 2026. onclive.com
- Verheij FS, et al. Long-term results of organ preservation with total neoadjuvant therapy: the OPRA trial. J Clin Oncol 2024. doi:10.1200/JCO.23.01208
- Schrag D, et al. Preoperative treatment of locally advanced rectal cancer (PROSPECT). N Engl J Med 2023. doi:10.1056/NEJMoa2303269
- Scott AJ, et al. Management of locally advanced rectal cancer: ASCO guideline. J Clin Oncol 2024. doi:10.1200/JCO.24.01160
- Pearlman R, et al. Germline mutations among patients with early-onset colorectal cancer. JAMA Oncol 2017. doi:10.1001/jamaoncol.2016.5194
Bortezomib: once or twice a week?
78-year-old, new myeloma, kidneys failed from light chains, on dialysis, diabetic neuropathy in both feet. The fellow asks: should we go twice a week?
Cast nephropathy: free light chains clog the kidney tubules; the faster they fall, the better the kidney's chance. Free light chains: the blood test that tracks it. Weekly: days 1, 8, 15, 22 every 28 days. Twice weekly: days 1, 4, 8, 11 every 21 days, at least 72 hours apart.
Algorithm
What the studies show
| Study | Who | Disease control | Neuropathy |
|---|---|---|---|
| Bringhen, Blood 2010 | 511 older patients, phase 3 trial switched from twice weekly to weekly mid-study | 3-year PFS 50% weekly vs 47% twice | 8% vs 28%grade 3 or 4 |
| Moreau, Lancet Oncol 2011 | 222 relapsed, randomized subcutaneous vs IV, both twice weekly | Response 42% vs 42% | 6% vs 16%grade 3 or worse |
| Cook, Am J Hematol 2021 | 555 new patients on VRd, Mayo Clinic | Twice weekly reached best response faster; same PFS and survival | More with twice weekly |
| Hoff, Blood Cancer J 2024 | 2,497 new patients, US real-world data | PFS 37.2 vs 39.6 months, no difference | 18.5% vs 34.7%weekly vs twice |
Bottom line: twice weekly gets the response faster, not longer. It buys speed and costs nerves. PFS here is progression-free survival.
Why the kidney changes the answer
| Study | What it showed |
|---|---|
| Hutchison, Clin J Am Soc Nephrol 2009 | 19 patients on dialysis from cast nephropathy. The 13 with a sustained early fall in free light chains (median 85%) all came off dialysis, at a median of 27 days. Of 6 whose chemotherapy was interrupted by infection, only 1 recovered. |
| MYRE, Bridoux, JAMA 2017 | 98 patients with biopsy-proven cast nephropathy, all on bortezomib and dexamethasone, randomized to two dialysis filters. Off dialysis at 3 months: 41% vs 33% (not significant); at 12 months: 61% vs 38%. It tested the filter, not the bortezomib schedule or cyclophosphamide. |
Read together: in cast nephropathy the clock is the light chain level. Interrupted chemotherapy is the real enemy, which is why an infection on board weighs heavily.
Order and check
- Serum free light chains on days 1, 8 and 15
- Neuropathy grade before every dose
- Platelets before every dose
- Acyclovir for zoster prophylaxis
- On dialysis: give after the session; no renal dose change
- Liver: bilirubin over 1.5 times normal, start at 0.7 mg/m2
Write it like this
Newly diagnosed multiple myeloma with dialysis-dependent acute kidney injury, presumed light chain cast nephropathy, renal biopsy pending. Bortezomib-based induction with subcutaneous bortezomib weekly given baseline diabetic neuropathy and active infection. Serum free light chains on days 8 and 15; if not falling steeply, will intensify bortezomib to twice weekly or add daratumumab. Neuropathy assessed before each dose.
Where people slip
- Twice weekly for everyone. It doubles neuropathy without longer disease control outside an emergency.
- Waiting for the end of cycle 1 to look at light chains in cast nephropathy. Day 8 and 15 tell you whether the kidney has a chance.
- IV instead of subcutaneous. Same response, a third of the severe neuropathy.
Twice weekly buys speed, not survival. The kidney is the emergency; the nerve is the price.
Sources
Retrieved from PubMed and the FDA label, read on Nov 9, 2026.
- Bringhen S, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010. doi:10.1182/blood-2010-07-294983
- Moreau P, et al. Subcutaneous versus intravenous bortezomib in relapsed multiple myeloma. Lancet Oncol 2011. doi:10.1016/S1470-2045(11)70081-X
- Cook J, et al. Outcomes with different administration schedules of bortezomib in VRd as first-line therapy. Am J Hematol 2021. doi:10.1002/ajh.26074
- Hoff FW, et al. Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis. Blood Cancer J 2024. doi:10.1038/s41408-024-01034-6
- Hutchison CA, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009. doi:10.2215/CJN.04590908
- Bridoux F, et al. High-cutoff vs conventional hemodialysis in myeloma cast nephropathy (MYRE). JAMA 2017. doi:10.1001/jama.2017.17924
- Bortezomib (Velcade) prescribing information, FDA: dosing, neuropathy and liver dose changes.